Indian Patent Office rejects Sovaldi patent, paves way for generics

The Indian Patent Office (IPO) has rejected one of US drug maker Gilead’s patent applications to cover hepatitis C drug Sovaldi (sofosbuvir), in a decision that may decrease the blockbuster’s cost in the country.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

‘Blatant imitation’: Indian court blocks copycat pharma branding

22 June 2026 The court granted Blue Cross Laboratories a permanent injunction after finding that a rival product’s mark and packaging closely mirrored its own.

Asia

Takeda’s China IP head: What pharma is still getting wrong

27 May 2026 China’s IP system is undergoing real change. Takeda’s IP head for the region explains what that looks like on the ground and why the old playbook no longer cuts it.

Asia

WATCH: China patent landscape

24 May 2026 The regulatory and IP environment in China is shifting at a rapid pace, bringing new measures, guiding cases, and compliance hurdles. This session provides a high-level overview of the past year’s critical changes and what life sciences companies must anticipate on the horizon.

More features

Buying the brains: Why is Big Pharma shopping for innovation?

FisherBroyles and Hong Kong affiliate draft in senior partners

‘Engagement and collaboration’: New IP Federation president builds on strong foundations

AbbVie, Allergan takes on Swiss aesthetics rival over syringe design

Trump slaps 100% tariff on generic drugs in US manufacturing push

UK Prime Minister axes science ministry in govt shakeup

Masimo keeps $634m smartwatch award and moves to appeal

Arbutus takes Comirnaty LNP patent fight to Canada and UPC

Indian Patent Office rejects Sovaldi patent, paves way for generics

More on this story

Editor's picks

Editor's picks

More features